[1] van Grootheest K, de Jong-van den Berg L. Patients' role in reporting adverse drug reactions[J]. Expert opinion on drug safety, 2004, 3(4): 363-368.
[2] 曾繁典. 世界卫生组织药物警戒指标及其应用[J]. 医药导报, 2016, 35(11):1159-1163.
[3] H rmark L, van Hunsel F, Grundmark B. ADR reporting by the general public: lessons learnt from the Dutch and Swedish systems[J]. Drug safety, 2015, 38(4): 337-347.
[4] 丁呈怡, 詹思延. 药品使用者自发报告的价值与促进策略[J]. 药物流行病学杂志, 2016, 25(1):55-58.
[5] 国家食品药品监督管理总局.国家药品不良反应监测年度报告(2016年)[EB/OL]. (2017-04-28)[2017-06-01]. http://www.cfda.gov.cn/WS01/CL0844/172167.html.
[6] 边蕾,赵频,杨悦.药物警戒中患者直接报告情况研究[J].中国药物警戒, 2013, 10(10):609-613.
[7] van Hunsel F, H rmark L, Pal S, et al. Experiences with adverse drug reaction reporting by patients: an 11-country survey[J]. Drug safety, 2012, 35(1): 45-60.
[8] 方素清. 论英国黄卡制度对我国药品不良反应监测的启示[J]. 国际医药卫生导报, 2006, 12(23): 100-102.
[9] 刘巍, 陈易新. 美国药品不良反应信息收集系统分析与启示[J]. 中国执业药师, 2008, 5(12): 25-27.
[10] 吴桂芝, 王春婷, 张力. 药品不良反应自发报告系统信息采集内容和方式的分析[J]. 中国药物警戒, 2011, 8(10) : 596-599.
[11] 陆逸雁, 李虹影, 盛红彬, 等. 不同人群药品不良反应认知度调查[J]. 中国药物警戒, 2009, 6(3): 147-151.
[12] van Hunsel F, van der Welle C, Passier A, et al. Motives for reporting adverse drug reactions by patient-reporters in the Netherlands[J]. European journal of clinical pharmacology, 2010, 66(11): 1143-1150.
[13] van Hunsel F P A M, ten Berge E A A M, Borgsteede S D, et al. What motivates patients to report an adverse drug reaction?[J]. Annals of Pharmacotherapy, 2010, 44(5): 936-937.
[14] Yamamoto M, Kubota K, Okazaki M, et al. Patients views and experiences in online reporting adverse drug reactions: findings of a national pilot study in Japan[J]. Patient Preference & Adherence, 2015, 9(default): 173-184.
[15] 郑明节, 王春婷. 我国患者报告药品不良反应的现状和对策分析[J]. 中国药物警戒, 2014,11(10):618-620. |